Shanna Miranti, MPAS, PA-C

Shanna Miranti, MPAS, PA-C, discusses the Umary hyaluronic acid tablets that were recalled in fall 2024.

A panelist discusses how the choice between systemic and topical treatments for pediatric atopic dermatitis (AD) depends on factors such as disease severity, impact on quality of life, affected body surface area, and response to previous therapies.

A panelist discusses how atopic dermatitis presents and is managed differently in adults vs children, with adults typically experiencing more localized lesions and chronic lichenification while children tend to have more widespread involvement and acute inflammation.

Join Dermatology Times’ quarterly editor in chief Shanna Miranti, MPAS, PA-C, in a look back at acne milestones in 2024 such as topical clindamycin, adapalene, and benzoyl peroxide gel (Cabtreo).

At the SDPA Fall Conference, Miranti emphasized the importance of targeted, comprehensive acne therapies and inspired attendees to embrace pediatric dermatology as a rewarding subspecialty.

Shanna Miranti, MMS, PA-C, reviews 2 patient cases of pseudo acne fulminans, offering perspectives on treatment and management strategies.

It is important that dermatology providers can easily recognize and treat communicable sports dermatoses, writes Shanna Miranti, MMS, PA-C.

Young patients are heading back to school, and common skin issues like acne, eczema, warts, and pigmentation can affect their confidence, Shanna Miranti, MPAS, PA-C, writes.

Dermatology Times' Summer Editor in Chief, Shanna Miranti, MPAS, PA-C, shares how she has learned to be happy, stay humble, and be brilliant in her more than 22 years in dermatology.

Miranti previews her sessions from the meeting which kicks off tomorrow, May 30, in Orlando, Florida.

Miranti presented tips on handling denial hurdles and how to ensure patients receive access to the treatments they need.

Shanna Miranti, MPAS, PA-C, shares updates on the status of roflumilast foam 0.3% and Cabtreo available in US pharmacies.

Aaron Farberg, MD, and Shanna Miranti, MPAS, PA-C, discuss the upcoming approvals of nivolumab and IDP-126.

Verrica’s VP-102 is the first FDA-approved treatment for molluscum lesions.

Dermatology advanced practice providers work alongside physicians to improve patient care and access.